1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Alpelisib
Trade Name:
Piqray
Manufacturer/Distributor:
Novartis Pharmaceuticals Canada Inc.
Classification:
Antineoplastic agent
ATC Class:
L01EX65 - alpelisib
Status:
active
Notice of Compliance (yyyy/mm/dd):
2020/03/11
Date Marketed in Canada (yyyy/mm/dd):
2020/03/11
Presentation:
Tablet: 50 mg. DIN: 02497042
Tablet: 150 mg. DIN: 02497069
Tablet: 200 mg. DIN: 02497077
Tablet: kit with 50 mg and 200 mg tablets. DIN: 02497085
Comments:
In combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.
Back to:
Drug Product Listings 
